ANBT
CTXR icon

American National Bank & Trust’s Citius Pharmaceuticals CTXR Stock Holding History

American National Bank & Trust’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40
Closed -$757 – 496
2023
Q4 		$757 Buy
+40
New +$759 ﹤0.01% 513

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

American National Bank & Trust's CTXR Position: Q1 2024 in Review

American National Bank & Trust sold out of Citius Pharmaceuticals (CTXR) in Q1 2024, closing a stake of 40 shares — an estimated $757 sold.

American National Bank & Trust first reported a position in CTXR in Q4 2023 and held it in 1 quarter. The position peaked at $757 in Q4 2023. 73 funds tracked by Wall St. Rank hold CTXR as of Q1 2024.

  • American National Bank & Trust reported no remaining Citius Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • American National Bank & Trust sold 40 Citius Pharmaceuticals shares in Q1 2024, an estimated $757.
  • American National Bank & Trust first reported a position in Citius Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • American National Bank & Trust's Citius Pharmaceuticals position peaked at $757 in Q4 2023.
  • 73 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2024.

Based on American National Bank & Trust's 13F filing for Q1 2024, filed 10 Apr 2024.